Johnson & Johnson (JNJ) Gross Margin (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Gross Margin came in at 68.19% in Q2 2026, up 32.0% year-over-year from 51.66% in Q2 2025, and up 2.83% quarter-over-quarter from 66.31% in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Gross Margin (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Gross Margin across 18 years of filings, most recently posting 68.19% for Q2 2026.
- In Q2 2026, Gross Margin rose 32.0% year-over-year to 68.19%; the TTM figure through Jun 2026 stood at 67.91% (down 1.0% YoY), while the FY2025 annual figure was 67.88%, down 119.0% from the prior year.
- Gross Margin came in at 68.19% for Q2 2026 at Johnson & Johnson, up from 66.31% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 69.97% in Q3 2023 to a low of 66.31% in Q1 2026.
- Average Gross Margin over 5 years is 68.58%, with a median of 68.87% recorded in 2024.
- Year-over-year, Gross Margin jumped 155 bps in 2024 and sank 315 bps in 2025.
- Over 5 years, Gross Margin stood at 69.13% in 2022, then declined by 1 bps to 68.23% in 2023, then gained by 0 bps to 68.35% in 2024, then slipped by 1 bps to 67.56% in 2025, then increased by 1 bps to 68.19% in 2026.
- Per Business Quant data, the three most recent Gross Margin figures were 68.19% in Q2 2026, 66.31% in Q1 2026, and 67.56% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 68.19% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 74.74% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 73.54% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 78.02% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 72.78% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 80.05% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 93.73% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 87.30% |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 97.58% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 68.19% |
| Mar 29, 2026 | 66.31% |
| Dec 28, 2025 | 67.56% |
| Sep 28, 2025 | 69.56% |
| Jun 29, 2025 | 67.87% |
| Mar 30, 2025 | 66.40% |
| Dec 29, 2024 | 68.35% |
| Sep 29, 2024 | 69.01% |
| Jun 30, 2024 | 69.40% |
| Mar 31, 2024 | 69.55% |
| Dec 31, 2023 | 68.23% |
| Oct 1, 2023 | 69.06% |
| Jul 2, 2023 | 69.97% |
| Apr 2, 2023 | 68.00% |
| Jan 1, 2023 | 69.49% |
| Oct 2, 2022 | 69.13% |
| Jul 3, 2022 | 68.73% |
| Apr 3, 2022 | 69.67% |
| Oct 3, 2021 | 68.93% |
| Jul 4, 2021 | 67.45% |